TABLE 3.
Comparison of clinical, biochemical, and coagulation data of patients before and following five courses of plasma exchange
| Reference range | Pre‐plasma exchange median (IQR) | Post‐plasma exchange median (IQR) | P‐value | |
|---|---|---|---|---|
| P:F ratio (mm Hg) | >53 | 11.5 (10.8‐19.7) | 18.1 (16.0‐24.9) | .031 |
| Creatinine (μmol/L) | 49‐90 | 54 (42‐68) | 46 (39‐62) | .344 |
| Platelets (109/L) | 150‐400 | 263 (240‐410) | 345 (309‐442) | .297 |
| Lymphocyte (109/L) | 1.0‐4.8 | 0.91 (0.53‐1.10) | 1.40 (0.90‐1.95) | .047 |
| D‐ dimer (ug/L FEU) | 0‐550 | 4110 (2690‐6483) | 2385 (968‐3790) | .039 |
| LDH (IU/L) | 90‐235 | 431 (399‐595) | 426 (308‐446) | .188 |
| CRP (mg/L) | 0‐5 | 300 (128‐349) | 167 (38‐271) | .109 |
| Ferritin (ng/mL) | 10‐300 | 1003 (514‐3373) | 568 (331‐685) | .016 |
| ADAMTS13 activity (%) | 60‐146 | 75 (66‐83) | 79 (77‐83) | .375 |
| VWF activity (IU/mL) | 0.5‐1.87 | 2.68 (2.07‐5.05) | 1.46 (1.08‐3.00) | .016 |
| VWF antigen (IU/mL) | 0.5‐1.6 | 3.6 (2.1‐5.2) | 1.7 (1.4‐2.3) | .016 |
| VWF Antigen/ADAMTS13 ratio | 0.34‐2.7 | 4.4 (2.7‐7.4) | 2.2 (1.7‐2.9) | .016 |
| Factor VIII (IU/mL) | 0.5‐2.0 | 2.2 (1.7‐5.3) | 1.3 (1.0‐2.0) | .016 |
| Fibrinogen (g/L) | 1.5‐4.0 | 4.96 (4.41‐9.50) | 3.98 (3.39‐4.93) | .031 |
| TNF‐alpha (pg/mL) | 0‐16 | 4.4 (3.0‐8.2) | 4.6 (3.0‐8.2) | >.999 |
| IL‐1b (pg/mL) | 0‐5 | 0.19 (0.10‐0.47) | 0.22 (0.12‐0.52) | .625 |
| IL‐6 (pg/mL) | 5‐15 | 27 (8‐52) | 18 (10‐117) | >.999 |
| IL‐10 (pg/mL) | 0‐10 | 3.5 (1.98‐5.1) | 2.5 (1.5‐4.0) | .313 |
A summary of the impact of PEX on thrombotic, inflammatory, and cytokine parameters and organ function measured before initiation of and on completion of PEX.
n = 7; apart from P:F ratio (n = 6); LDH (n = 5); serum cytokines (n = 5), and serum creatinine (n = 6).
Data are expressed as median and interquartile range.